{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T06:30:41Z","timestamp":1764225041565},"reference-count":43,"publisher":"American Society for Microbiology","issue":"2","license":[{"start":{"date-parts":[[2011,2,1]],"date-time":"2011-02-01T00:00:00Z","timestamp":1296518400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2011,2]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            <jats:italic>Yersinia pestis<\/jats:italic>\n            , the causative agent of bubonic, septicemic, and pneumonic plague, is classified as a CDC category A bioterrorism pathogen. Streptomycin and doxycycline are the \u201cgold standards\u201d for the treatment of plague. However, streptomycin is not available in many countries, and\n            <jats:italic>Y. pestis<\/jats:italic>\n            isolates resistant to streptomycin and doxycycline occur naturally and have been generated in laboratories. Moxifloxacin is a fluoroquinolone antibiotic that demonstrates potent activity against\n            <jats:italic>Y. pestis<\/jats:italic>\n            in\n            <jats:italic>in vitro<\/jats:italic>\n            and animal infection models. However, the dose and frequency of administration of moxifloxacin that would be predicted to optimize treatment efficacy in humans while preventing the emergence of resistance are unknown. Therefore, dose range and dose fractionation studies for moxifloxacin were conducted for\n            <jats:italic>Y. pestis<\/jats:italic>\n            in an\n            <jats:italic>in vitro<\/jats:italic>\n            pharmacodynamic model in which the half-lives of moxifloxacin in human serum were simulated so as to identify the lowest drug exposure and the schedule of administration that are linked with killing of\n            <jats:italic>Y. pestis<\/jats:italic>\n            and with the suppression of resistance. In the dose range studies, simulated moxifloxacin regimens of \u2265175 mg\/day killed drug-susceptible bacteria without resistance amplification. Dose fractionation studies demonstrated that the AUC (area under the concentration-time curve)\/MIC ratio predicted kill of drug-susceptible\n            <jats:italic>Y. pestis<\/jats:italic>\n            , while the\n            <jats:italic>C<\/jats:italic>\n            <jats:sub>max<\/jats:sub>\n            (maximum concentration of the drug in serum)\/MIC ratio was linked to resistance prevention. Monte Carlo simulations predicted that moxifloxacin at 400 mg\/day would successfully treat human infection due to\n            <jats:italic>Y. pestis<\/jats:italic>\n            in 99.8% of subjects and would prevent resistance amplification. We conclude that in an\n            <jats:italic>in vitro<\/jats:italic>\n            pharmacodynamic model, the clinically prescribed moxifloxacin regimen of 400 mg\/day is predicted to be highly effective for the treatment of\n            <jats:italic>Y. pestis<\/jats:italic>\n            infections in humans. Studies of moxifloxacin in animal models of plague are warranted.\n          <\/jats:p>","DOI":"10.1128\/aac.00818-10","type":"journal-article","created":{"date-parts":[[2010,11,30]],"date-time":"2010-11-30T09:45:25Z","timestamp":1291110325000},"page":"822-830","update-policy":"http:\/\/dx.doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":17,"title":["Use of an\n            <i>In<\/i>\n            <i>Vitro<\/i>\n            Pharmacodynamic Model To Derive a Moxifloxacin Regimen That Optimizes Kill of\n            <i>Yersinia pestis<\/i>\n            and Prevents Emergence of Resistance"],"prefix":"10.1128","volume":"55","author":[{"given":"A.","family":"Louie","sequence":"first","affiliation":[{"name":"Ordway Research Institute, Albany, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H. S.","family":"Heine","sequence":"additional","affiliation":[{"name":"U.S. Army Medical Research Institute of Infectious Diseases, Fort Detrick, Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"VanScoy","sequence":"additional","affiliation":[{"name":"Ordway Research Institute, Albany, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Eichas","sequence":"additional","affiliation":[{"name":"Ordway Research Institute, Albany, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Files","sequence":"additional","affiliation":[{"name":"Ordway Research Institute, Albany, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Fikes","sequence":"additional","affiliation":[{"name":"Ordway Research Institute, Albany, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D. L.","family":"Brown","sequence":"additional","affiliation":[{"name":"Ordway Research Institute, Albany, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.","family":"Liu","sequence":"additional","affiliation":[{"name":"Ordway Research Institute, Albany, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Kinzig-Schippers","sequence":"additional","affiliation":[{"name":"Institute for Biomedical and Pharmaceutical Research, Nu\u0308rnberg-Heroldsberg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"So\u0308rgel","sequence":"additional","affiliation":[{"name":"Institute for Biomedical and Pharmaceutical Research, Nu\u0308rnberg-Heroldsberg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G. L.","family":"Drusano","sequence":"additional","affiliation":[{"name":"Ordway Research Institute, Albany, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","unstructured":"Biohazard. 1999"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00251-07"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.6.1665-1670.2002"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.12.3935-3941.2003"},{"key":"e_1_3_2_6_2","first-page":"16S","volume":"88","year":"1990","unstructured":"Appel, G. B. 1990. Aminoglycoside nephrotoxicity. Am. J. Med. 88(Suppl. C):16S-20S.","journal-title":"Am. J. Med."},{"key":"e_1_3_2_7_2","first-page":"423","volume":"13","year":"1914","unstructured":"Bacot, A. W., and C. J. Martin. 1914. Observations on the mechanism of the transmission of plague by fleas. J. Hyg. (Lond.) 13(Suppl.):423-439.","journal-title":"J. Hyg. (Lond.)"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.31.7.1054"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.38.3.481"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1086\/381545"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.33.6.797"},{"key":"e_1_3_2_12_2","first-page":"2691","year":"2005","unstructured":"Butler, T., and D. T. Dennis. 2005. Yersinia species, including plague, p. 2691-2701. In G. L. Mandell, J. E. Bennett, and R. Dolin (ed.), Principles and practices of infectious diseases, 6th ed. Elsevier\/Churchill Livingstone, Philadelphia, PA.","journal-title":"Principles and practices of infectious diseases"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1086\/604718"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.3.675"},{"key":"e_1_3_2_15_2","first-page":"617","volume":"46","year":"1997","unstructured":"Centers for Disease Control and Prevention. 1997. Fatal human plague\u2014Arizona and Colorado, 1996. MMWR Morb. Mortal. Wkly. Rep. 46:617-620.","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"e_1_3_2_16_2","unstructured":"Methods for dilution antimicrobial susceptibility testing for bacteria that grow aerobically. 2006"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1967.03130170165036"},{"key":"e_1_3_2_18_2","unstructured":"A program for simulation identification and optimal experimental design. 1997"},{"key":"e_1_3_2_19_2","first-page":"21","year":"1997","unstructured":"Dennis, D., and F. Meier. 1997. Plague, p. 21-47. In C. R. Horsburgh and A. M. Nelson (ed.), Pathology of emerging infections. ASM Press, Washington, DC.","journal-title":"Pathology of emerging infections"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.12.5099-5106.2005"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.40.11.2646"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199709043371004"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01533-06"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.283.17.2281"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1086\/367570"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.39.10.3649-3655.2001"},{"key":"e_1_3_2_27_2","first-page":"36","year":"2007","unstructured":"Louie, A., et al. 2007. Dose-ranging and dose-fractionation studies of moxifloxacin against Bacillus anthracis, abstr. A-1442, p. 36. Abstr. 47th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.","journal-title":"Dose-ranging and dose-fractionation studies of moxifloxacin against Bacillus anthracis"},{"key":"e_1_3_2_28_2","first-page":"30","year":"2008","unstructured":"Louie, A., et al. 2008. Pharmacodynamic optimization of gentamicin against Yersinia pestis in an in vitro pharmacodynamic model, abstr. A-1827, p. 30. Abstr. 48th Annu. Intersci. Conf. Antimicrob. Agents Chemother. (ICAAC)-Infect. Dis. Soc. Am. (IDSA) 46th Annu. Meet. American Society for Microbiology and Infectious Diseases Society of America, Washington, DC.","journal-title":"Pharmacodynamic optimization of gentamicin against Yersinia pestis in an in vitro pharmacodynamic model"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00073-07"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01439-07"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/92.3.273"},{"key":"e_1_3_2_32_2","first-page":"2157","year":"2000","unstructured":"Medical Economics Co. 2000. Physicians' desk reference, p. 2157-2165. Medical Economics Co., Montvale, NJ.","journal-title":"Physicians' desk reference"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00647-07"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1086\/500137"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.10.1.35"},{"key":"e_1_3_2_36_2","first-page":"37","volume":"56","year":"1989","unstructured":"Rasoamanana, B., P. Coulanges, P. Michel, and N. Rasolofonirina. 1989. Sensitivity of Yersinia pestis to antibiotics: 277 strains isolated in Madagascar between 1926 and 1989. Arch. Inst. Pasteur Madagascar 56:37-53.","journal-title":"Inst. Pasteur Madagascar"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/37.4.769"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/41.2.301"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/0035-9203(89)90247-2"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.39.9.2153"},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2004.06.011"},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.43.11.2793"},{"key":"e_1_3_2_43_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1984.03340310043018"},{"key":"e_1_3_2_44_2","doi-asserted-by":"publisher","DOI":"10.3201\/eid0809.010536"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00818-10","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00818-10","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T23:22:25Z","timestamp":1645485745000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.00818-10"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,2]]},"references-count":43,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,2]]}},"alternative-id":["10.1128\/AAC.00818-10"],"URL":"https:\/\/doi.org\/10.1128\/aac.00818-10","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,2]]},"assertion":[{"value":"2010-06-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2010-11-16","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2011-01-20","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}